These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9800719)

  • 41. [Generics as therapeutic resources].
    Riverro-Serrano O; Juan-Lopez M; Lerdo-de Tejada F; Montoya-Cabrera MA; Camacho-Solís R; Valenzuela-Gomez Gallardo F; Lifshitz A; Gamboa-Marrufo J; Martínez-Domínguez M
    Gac Med Mex; 1998; 134(2):169-206. PubMed ID: 9618996
    [No Abstract]   [Full Text] [Related]  

  • 42. Biosimilars in clinical practice.
    Mikhail A
    Kidney Blood Press Res; 2007; 30 Suppl 1():18-22. PubMed ID: 17726339
    [No Abstract]   [Full Text] [Related]  

  • 43. The importance of brand continuity in epilepsy drugs.
    Goodwin M
    Nurs Times; 2005 Jun 21-27; 101(25):26-7. PubMed ID: 15997944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The new pharmacy law--for the best of the state or the patients?].
    Vigen T
    Tidsskr Nor Laegeforen; 1999 Oct; 119(26):3883. PubMed ID: 10592742
    [No Abstract]   [Full Text] [Related]  

  • 45. Comments on the note for guidance on bioavailability and bioequivalence in the European Union.
    Calvo G
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():11. PubMed ID: 9800721
    [No Abstract]   [Full Text] [Related]  

  • 46. Switching to generic: the need for physician and patient consent when substituting antiepileptic medication.
    Langdon EH
    J Contemp Health Law Policy; 2008; 25(1):166-95. PubMed ID: 19137751
    [No Abstract]   [Full Text] [Related]  

  • 47. Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting.
    Lamarque V; Merle L; Demarez JP;
    Therapie; 2008; 63(4):301-9. PubMed ID: 18937910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generic medications: another variable in the treatment of illnesses.
    Blier P
    J Psychopharmacol; 2007 Jul; 21(5):459-60. PubMed ID: 17664245
    [No Abstract]   [Full Text] [Related]  

  • 49. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 51. Greater access to generic drugs. New FDA initiatives to improve drug reviews and reduce legal loopholes.
    Meadows M
    FDA Consum; 2003; 37(5):12-7. PubMed ID: 14666900
    [No Abstract]   [Full Text] [Related]  

  • 52. Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?
    Benet LZ; Jayachandran P; Carroll KJ; Burmeister Getz E
    Clin Pharmacol Ther; 2019 Feb; 105(2):326-328. PubMed ID: 30652313
    [No Abstract]   [Full Text] [Related]  

  • 53. Medications: a safety issue for biosimilars.
    Palmisano D; Slakey D
    J La State Med Soc; 2012; 164(4):220. PubMed ID: 22953461
    [No Abstract]   [Full Text] [Related]  

  • 54. [Generic drugs, alternatives, substitutes, interchanges].
    Kolár J; Chalabala M
    Ceska Slov Farm; 1999 Mar; 48(2):59-64. PubMed ID: 10376417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy.
    Liow K; Barkley GL; Pollard JR; Harden CL; Bazil CW;
    Neurology; 2007 Apr; 68(16):1249-50. PubMed ID: 17438213
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapeutic equivalency of generic antiepileptic drugs: results of a survey.
    Wilner AN
    Epilepsy Behav; 2004 Dec; 5(6):995-8. PubMed ID: 15582850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generic anti-arrhythmic drugs.
    Obel IW
    Cardiovasc J S Afr; 2002; 13(3):131; author reply 132-3. PubMed ID: 12193966
    [No Abstract]   [Full Text] [Related]  

  • 58. [Biosimilar products comparable to original preparations. The Medical Products Agency will not yet classify the agents as generics].
    Welin M; Liliemark J
    Lakartidningen; 2009 Jun 3-9; 106(23):1547-8. PubMed ID: 19583011
    [No Abstract]   [Full Text] [Related]  

  • 59. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers.
    Bongiorno RA; Nutescu EA
    Semin Thromb Hemost; 2004 Dec; 30(6):619-26. PubMed ID: 15630667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug companies lobby against generic versions of biologics.
    Tucker ME
    BMJ; 2013 Feb; 346():f740. PubMed ID: 23381589
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.